Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).

Nizar M Tannir Maria Nirvana FormigaKonstantin PenkovNikolay KislovAleksandr VasilievNils Gunnar SkareWalter HongStanley Dai Lily TangAnila QureshiJonathan ZalevskyMary A Tagliaferri Daniel J George Archana M Agarwal Sumanta Kumar Pal

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

First-line BEMPEG plus NIVO for advanced/metastatic ccRCC did not improve efficacy in patients with intermediate-/poor-risk disease but led to fewer grade 3/4 TRAEs versus TKI.

Keyphrases

phase iii
open label
clinical trial
squamous cell carcinoma
small cell lung cancer
tyrosine kinase
double blind
renal cell carcinoma
advanced non small cell lung cancer